An International, Multicentre, Efficacy and Safety Study of I10E in Initial and Maintenance Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.
Phase of Trial: Phase III
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Immune globulin (Primary)
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy
- Focus Registrational; Therapeutic Use
- Acronyms PRISM
- Sponsors LFB Biotechnologies
- 02 Aug 2017 The trial has been completed in Germany.
- 12 Sep 2016 Planned End Date changed from 1 Apr 2017 to 1 Jun 2017.
- 12 Sep 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Jun 2017.